Health · Corrected
FDA Investigates Tumor Risk Tied to Zolgensma Gene Therapy
Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources
Brief
The Food and Drug Administration said on Friday, Nov. 6, that it is investigating a serious risk of tumors, including cancer, in patients given Zolgensma…
Keep reading with NewsPlain Premium
Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.
3 sources behind this story.
Updates
Correction, : Correction: The approximately $1.1 billion in sales for the first nine months of 2026 covers Novartis’s Zolgensma Group, which includes Itvisma, rather than Zolgensma alone.